THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Michael Cookson to Prostate-Specific Antigen

This is a "connection" page, showing publications Michael Cookson has written about Prostate-Specific Antigen.
Connection Strength

2.686
  1. Prostate cancer: Could sensitive PSA assays expedite salvage radiotherapy? Nat Rev Urol. 2014 Jan; 11(1):14-5.
    View in: PubMed
    Score: 0.430
  2. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007 Feb; 177(2):540-5.
    View in: PubMed
    Score: 0.268
  3. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 2006 Jun; 97(6):1169-72.
    View in: PubMed
    Score: 0.256
  4. A pilot randomized clinical trial of a smartphone-based application to support at-home PSA screening and culturally tailored prostate cancer education for African American men: A study protocol. Contemp Clin Trials. 2024 Dec; 147:107737.
    View in: PubMed
    Score: 0.230
  5. The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA. Urol Oncol. 2002 Sep-Oct; 7(5):195-8.
    View in: PubMed
    Score: 0.197
  6. Health related quality of life assessment after radical prostatectomy in men with prostate specific antigen only recurrence. J Urol. 2001 Dec; 166(6):2286-90.
    View in: PubMed
    Score: 0.187
  7. Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen. J Urol. 2001 Feb; 165(2):455-8.
    View in: PubMed
    Score: 0.177
  8. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy. Urology. 1997 Jun; 49(6):887-93.
    View in: PubMed
    Score: 0.137
  9. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels. J Urol. 1995 Sep; 154(3):1070-3.
    View in: PubMed
    Score: 0.121
  10. Spurious elevation of serum PSA after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies. Prostate Cancer Prostatic Dis. 2012 Jun; 15(2):182-8.
    View in: PubMed
    Score: 0.093
  11. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol. 2009 May; 181(5):2064-70.
    View in: PubMed
    Score: 0.078
  12. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol. 2007 Dec; 178(6):2385-9; discussion 2389-90.
    View in: PubMed
    Score: 0.070
  13. Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men. Prostate Cancer Prostatic Dis. 2008; 11(3):264-9.
    View in: PubMed
    Score: 0.070
  14. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis. 2007; 10(2):137-42.
    View in: PubMed
    Score: 0.066
  15. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer. 2006 Nov 15; 107(10):2361-7.
    View in: PubMed
    Score: 0.066
  16. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol. 2002 May; 167(5):2032-5; discussion 2036.
    View in: PubMed
    Score: 0.048
  17. Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores. BJU Int. 2001 Nov; 88(7):722-6.
    View in: PubMed
    Score: 0.047
  18. Update on transrectal ultrasound-guided needle biopsy of the prostate. Mol Urol. 2000; 4(3):93-7; discussion 99.
    View in: PubMed
    Score: 0.041
  19. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Br J Urol. 1997 Mar; 79(3):432-8.
    View in: PubMed
    Score: 0.034
  20. The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes Control. 2011 Mar; 22(3):417-26.
    View in: PubMed
    Score: 0.022
  21. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007 Jun; 177(6):2106-31.
    View in: PubMed
    Score: 0.017
  22. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81.
    View in: PubMed
    Score: 0.017
  23. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol. 2003 Jan; 169(1):145-7; discussion 147-8.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES